3
Announcements
Trials
Browse
Landscape
Phase
Phase 1
1
Status
Completed
3
Active not recruiting
1
Sponsor Class
INDUSTRY
1
Study Type
Interventional
1
Sponsor
Cancer Type
Genitourinary
2
Plasma cell
1
Gynecologic
1
Conditions
Multiple Myeloma
292
Lymphoma
45
Recurrence
31
Neoplasms, Plasma Cell
28
Hematologic Neoplasms
25
Smoldering Multiple Myeloma
20
Lymphoma, Non-Hodgkin
20
Neoplasms
13
Leukemia, Lymphocytic, Chronic, B-Cell
11
Myelodysplastic Syndromes
10
Leukemia
10
Immunoglobulin Light-chain Amyloidosis
10
Leukemia, Myeloid, Acute
9
Precursor Cell Lymphoblastic Leukemia-Lymphoma
8
Myeloproliferative Disorders
8
Hodgkin Disease
8
Waldenstrom Macroglobulinemia
7
Lymphoma, Mantle-Cell
6
Prostatic Neoplasms
5
Paraproteinemias
5
Lymphoma, Large B-Cell, Diffuse
5
Lymphoma, Follicular
5
Lymphoma, B-Cell, Marginal Zone
5
Breast Neoplasms
5
Lymphoproliferative Disorders
4
Leukemia, Myelogenous, Chronic, BCR-ABL Positive
4
Hematologic Diseases
4
Colorectal Neoplasms
4
Anemia, Refractory, with Excess of Blasts
4
Anemia, Aplastic
4
Interventions
belantamab mafodotin
1
Date Range
30 days
90 days
1 year
All
Options
Has results
Has announcements
Clinical Trials
1 trials
Recent
Start date
Enrollment
Active not recruiting
×
Kidney Failure, Chronic
×
Plasma cell
×
Clear all
NCT04398745
2025-05-23
DREAMM12
GlaxoSmithKline
Phase 1
Active not recruiting
36 enrolled